Stock Rating Upgrade
In the last week the Value Trend Rating for Avadel Pharmaceuticals plc (NASDAQ: AVDL) improved from D to C reflecting improving fundamentals and high Appreciation Potential.
Recent Price Action
Avadel Pharmaceuticals plc (NASDAQ: AVDL) stock rose slightly by 0.2% on 4/12/24. The stock closed at $15.99. Moreover, trading volume in this advance was above average at 120% of normal. The stock has been exceptionally strong relative to the market over the last nine months but has declined -3.6% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to exceed the cost of capital, AVDL is expected to be a major Value Builder.
Avadel Pharmaceuticals plc has a current Value Trend Rating of C (Low Neutral). This VT Rating improved in recent days from D previously. The Value Trend Rating reflects very contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Avadel Pharmaceuticals plc has a poor Appreciation Score of 20 but a good Power Rating of 76, leading to the Low Neutral Value Trend Rating.
Be the first to comment